FrancophonIA/ELRC3.0 huggingface dataset:
English: The recommended dose is one 2.5 mg tablet taken by mouth twice a day, usually for over one month (32 to 38 days) after a hip replacement or for 10 to 14 days after a knee replacement.
Estonian: Soovitatav annus on üks 2,5 mg tablett suu kaudu kaks korda ööpäevas, tavaliselt ühe kuu jooksul (32-38 päeva) pärast puusaliigese asendamist või 10-14 päeva jooksul pärast põlveliigese asendamist.
English: For more information about using Eliquis, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Eliquisi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eliquis have also been included in the summary of product characteristics and the package leaflet.
Estonian: Eliquisi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It is used in patients who have one or more risk factors, such as having had a previous stroke, having high blood pressure, diabetes, heart failure or being 75 years old or over.
Estonian: Ravimit kasutatakse patsientidel, kellel on vähemalt üks riskitegur, nt varasem insult, kõrge vererõhk, diabeet, südamepuudulikkus või vanus vähemalt 75 aastat.
English: What is Eliquis and what is it used for?
Estonian: Mis on Eliquis ja milleks seda kasutatakse?
English: The most frequent side effects with Eliquis (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), haemorrhage (bleeding), haematoma (a collection of blood under the skin), contusion (bruising), nausea (feeling sick), low blood pressure (hypotension), epistaxis (nose bleeds), haematuria (blood in urine), low blood platelet counts (thrombocytopenia), blood tests showing alanine aminotransferase and gamma-glutamyltransferase increase and skin rash.
Estonian: Eliquisi kõige sagedamad kõrvalnähud (võivad esineda 1 kuni 10 patsiendil 100st) on aneemia (erütrotsüütide ehk vere punaliblede vähesus), verejooks, suured ja väikesed verevalumid, iiveldus, madal vererõhk, ninaverejooks, hematuuria (verikusesus), trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus), alaniini aminotransferaasi (ALAT) ja gamma-glutamüüli transferaasi (GGT)
English: Eliquis must not be used in patients who are actively bleeding, or who have liver disease which leads to problems with blood clotting and an increased risk of bleeding.
Estonian: Eliquisi ei tohi kasutada patsiendid, kellel on aktiivne verejooks või kellel esineb hüübimisprobleeme tekitav või verejooksuriski suurendav maksahaigus.
English: Eliquis contains the active substance apixaban.
Estonian: Eliquis sisaldab toimeainena apiksabaani.
English: Other information about Eliquis
Estonian: Muu teave Eliquisi kohta
English: Some of these side effects are not seen with all the uses of Eliquis.
Estonian: Mõni neist kõrvalnähtudest ei esine Eliquisi kõigil näidustustel kasutamisel.
English: Eliquis was also shown to be effective in preventing strokes and arterial blood clots in patients with atrial fibrillation in two main studies: the first (in 18,201 patients) compared Eliquis with another medicine, warfarin, while the second (in 5,598 patients) compared Eliquis with aspirin.
Estonian: Eliquisi efektiivsus insultide ja arteritrombide ennetamisel kodade virvendusega patsientidel tõendati kahes põhiuuringus: esimeses uuringus (18 201 patsienti) võrreldi Eliquisi teise ravimi, varfariiniga, ning teises uuringus (5598 patsienti) võrreldi Eliquisi aspiriiniga.
English: The medicine must also not be used in patients with conditions putting them at risk of major bleeding, such as an ulcer in the gut, or in patients being treated with other anticoagulant medicines except in specific circumstances (see summary of product characteristics).
Estonian: Ravimit ei tohi kasutada ka patsiendid, kellel on suure verejooksuriskiga seisundid, nt seedetrakti haavand, ega patsiendid, kes juba saavad ravi teiste antikoagulantidega (hüübimisvastaste ravimitega), v.a eriolukordades (vt ravimi omaduste kokkuvõte).
English: For the full list of side effects and restrictions with Eliquis, see the package leaflet.
Estonian: Eliquisi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What are the risks associated with Eliquis?
Estonian: Mis riskid Eliquisiga kaasnevad?
English: The company that markets Eliquis will provide educational material for healthcare professionals expected to prescribe Eliquis that addresses the risk of bleeding during treatment.
Estonian: Eliquisi turustaja varustab Eliquisi eeldatavalt määravaid tervishoiutöötajaid teabematerjalidega, milles käsitletakse raviaegse verejooksu riski.
English: For the treatment of deep vein thrombosis and pulmonary embolism, the recommended dose is 10 mg twice a day for the first week, followed by 5 mg twice a day for at least 3 months.
Estonian: Süvaveenitromboosi ja kopsuarteri trombemboolia raviks on soovitatav annus 10 mg kaks korda ööpäevas esimesel nädalal ja seejärel vähemalt 3-kuuline ravi annusega 5 mg kaks korda ööpäevas.
English: In both studies, Eliquis was compared with enoxaparin (another medicine used to prevent blood clots).
Estonian: Mõlemas uuringus võrreldi Eliquisi enoksapariiniga (samuti trombide ennetamise ravim).
English: How is Eliquis used?
Estonian: Kuidas Eliquisi kasutatakse?
English: The yearly rates in the second study were 1.6% for patients taking Eliquis and 3.6% for patients taking aspirin.
Estonian: Teises uuringus oli vastav näitaja Eliquisi kasutanud patsientidel 1,6% ja aspiriini kasutanud patsientidel 3,6%.
English: How does Eliquis work?
Estonian: Kuidas Eliquis toimib?
English: The medicine's effectiveness was measured by looking at the number of patients who either had problems related to clotting in the veins or who died of any cause during the treatment period.
Estonian: Ravimi efektiivsust mõõdeti nende patsientide arvu järgi, kellel olid kas probleemid veenitrombidega või kes olid raviperioodi jooksul surnud mis tahes põhjusel.
English: In patients undergoing a knee replacement, the corresponding numbers were 15% (147 out of 976) for Eliquis compared with 24% (243 out of 997) for enoxaparin.
Estonian: Põlveliigese asendamise operatsiooni järel olid vastavad näitajad Eliquisi rühmas 15% (147 patsienti 976st) ja 24% enoksapariini rühmas (243 patsienti 997st).
English: In the prevention study in 2,482 patients, Eliquis was compared with placebo (a dummy treatment) and its effectiveness was measured by looking at the number of patients who either had problems related to clotting in the veins or who died of any cause during treatment.
Estonian: Ennetamise uuringus (2482 patsienti) võrreldi Eliquisi platseeboga (näiv ravim) ning efektiivsust mõõdeti nende patsientide arvu järgi, kellel esinesid kas veenitromboosiga seotud probleemid või kes olid ravi ajal surnud mis tahes põhjustel.
English: What benefits of Eliquis have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Eliquisi kasulikkus?
English: Eliquis was also effective at treating deep vein thrombosis and pulmonary embolism and preventing their reoccurrence in two main studies.
Estonian: Samuti oli Eliquis kahes põhiuuringus efektiivne süvaveenitromboosi ja kopsuarteri trombemboolia ravis ning nende kordumise ennetamisel.
English: Eliquis is a medicine used to prevent venous thromboembolism (blood clots in the veins) in adults following a hip or knee replacement operation.
Estonian: Eliquis on ravim, mida kasutatakse täiskasvanud patsientidel, et ennetada puusa- või põlveliigese asendamise operatsiooni järel venoosset trombembooliat (trombide teke veenides).
English: Similarly, patients with atrial fibrillation are at high risk of clots forming in the heart, which can reach the brain where they can cause a stroke.
Estonian: Ka kodade virvendusega patsientidel on suur trombide tekkimise risk südames, kust trombid võivad liikuda peaajju, kus põhjustavad insuldi.
English: By blocking factor Xa, it reduces the levels of thrombin in the blood, which reduces the risk of blood clots forming in the arteries and veins.
Estonian: Xa-hüübimisfaktorit blokeerides vähendab Eliquis vere trombiinisisaldust, mis omakorda vähendab arteri- ja veenitrombide tekke riski.
English: 2.3% of patients treated with Eliquis had a clot or died, compared with 2.7% of patients treated with enoxaparin plus warfarin, showing that Eliquis was as effective as the comparator treatment.
Estonian: Patsiente, kellel esines tromb või kes surid, oli Eliquisiga ravitud patsientidest 2,3% ning enoksapariini ja varfariiniga ravitud patsientidest 2,7%, mis tõendab, et ravi Eliquisiga oli sama efektiivne kui võrdlusravi.
English: It is also used in adults to treat deep vein thrombosis (blood clot in a deep vein, usually in the leg) and pulmonary embolism (clot in a blood vessel supplying the lungs), and to prevent their reoccurrence.
Estonian: Ravimit kasutatakse ka süvaveenitromboosiga (tromb süvaveenis, tavaliselt jalas) ja kopsuarteri trombembooliaga (tromb kopsu verega varustavas soones) täiskasvanute raviks ja nende seisundite kordumise ennetamiseks.
English: In patients undergoing a hip replacement, 1.4% of the patients who completed treatment with Eliquis (27 out of 1,949) had a clotting event or died from any cause, compared with 3.9% (74 out of 1,917) of the patients taking enoxaparin.
Estonian: Patsiente, kellel esines veenitrombe või kes surid mis tahes põhjusel puusaliigese asendamise operatsiooni järel, oli Eliquisi kasutanutest 1,4% (27 patsienti 1949st) ja enoksapariini kasutanutest 3,9% (74 patsienti 1917st).
English: An overview of Eliquis and why it is authorised in the EU
Estonian: Ülevaade ravimist Eliquis ja ELis müügiloa väljastamise põhjendus
English: 2.3% of patients taking Eliquis (2.5 mg twice a day) experienced a clot or died, compared with 9.3% of patients taking placebo.
Estonian: Patsiente, kellel esines tromb või kes surid, oli Eliquisi uuringurühmas (2,5 mg kaks korda ööpäevas) 2,3% ja platseeborühmas 9,3%.
English: Eliquis can only be obtained with a prescription.
Estonian: Eliquis on retseptiravim.
English: For patients with atrial fibrillation at risk of stroke or blood clots, the recommended dose is 5 mg taken twice a day.
Estonian: Kodade virvendusega patsientidel, kellel on insuldi- või trombirisk, on soovitatav annus 5 mg kaks korda ööpäevas.
English: In the study comparing Eliquis with warfarin, 1.3 % of the patients taking Eliquis had a stroke or clotting event every year compared with 1.6% of the patients taking warfarin.
Estonian: Eliquisi varfariiniga võrrelnud uuringus oli ühe aasta insuldi- või trombootilise tüsistuse risk Eliquisi uuringurühmas 1,3% ja varfariini rühmas 1,6%.
English: To prevent deep vein thrombosis and pulmonary embolism from reoccurring, the recommended dose is 2.5 mg twice a day.
Estonian: Süvaveenitromboosi ja kopsuarteri trombemboolia kordumise ennetamiseks on soovitatav annus 2,5 mg kaks korda ööpäevas.
English: Additionally, Eliquis is used to prevent stroke (caused by blood clots in the brain) and blood clots in other organs in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart).
Estonian: Peale selle kasutatakse Eliquisi insuldi (mille põhjustab tromb peaajus) ja teiste elundite trombide (soonesiseste verehüüvete) ennetamiseks kodade virvendusega (südamekodade kiire korrapäratu kokkutõmbumine) täiskasvanud patsientidel.
English: Patients undergoing hip or knee replacement surgery, who have had a recent trauma, or are confined to bed are at a high risk of blood clots forming in the veins, which can be dangerous and even fatal if they move to another part of the body such as the lungs.
Estonian: Puusa- või põlveliigese asendamise patsientidel, hiljutise traumaga patsientidel või voodihaigetel patsientidel on suur veenitrombide tekke risk.
English: This means that it blocks factor Xa, an enzyme that is involved in the production of thrombin.
Estonian: Eliquisi toimeaine apiksabaan on Xa-hüübimisfaktori inhibiitor, mis pärsib ensüümi Xa-hüübimisfaktorit, mis osaleb trombiini moodustumises.
English: The main measures of effectiveness were based on the number of strokes or clotting events that occurred during treatment.
Estonian: Efektiivsuse põhinäitaja aluseks oli insultide või trombootiliste (soonesiseste verehüüvetega seotud) tüsistuste arv ravi ajal.
English: Eliquis was effective at preventing blood clots in the veins following a hip or knee replacement in two main studies involving a total of 8,464 patients.
Estonian: Kahes põhiuuringus, kus osales kokku 8464 patsienti, oli Eliquis efektiivne veenitrombide ennetamisel pärast puusa- või põlveliigese asendamise operatsiooni.
English: In the treatment study conducted in 5,395 patients, Eliquis was compared with enoxaparin followed by warfarin; the main measure of effectiveness was based on the number of patients who either had blood clots in the veins of the legs or lungs or died because of this during the treatment period.
Estonian: Raviuuringus (5395 patsienti) võrreldi Eliquis-ravi enoksapariini- ja sellele järgneva varfariinraviga.
English: This summary was last updated in 01-2018.
Estonian: Kokkuvõtte viimane uuendus: 01-2018.
English: What measures are being taken to ensure the safe and effective use of Faslodex?
Estonian: Mis meetmed võetakse, et tagada Faslodexi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Faslodex on 10 March 2004.
Estonian: Euroopa Komisjon andis Faslodexi müügiloa, mis kehtib kogu Euroopa Liidus, 10. märtsil 2004.
English: The full EPAR for Faslodex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Faslodexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Medicines Agency concluded that the benefits seen in studies with Faslodex are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Faslodexi korral uuringutes täheldatud kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The recommended dose is 500 mg given once a month, with an additional 500-mg dose two weeks after the first dose.
Estonian: Soovitatav annus on 500 mg üks kord kuus ja 500 mg lisaannus kaks nädalat pärast esimest annust.
English: Other information about Faslodex
Estonian: Muu teave Faslodexi kohta
English: Faslodex must not be used in women who are pregnant or breast-feeding, or in patients who have severe liver disease.
Estonian: Faslodexi ei tohi kasutada rasedad või imetavad naised ega raske maksahaigusega patsiendid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Faslodex have been included in the summary of product characteristics and the package leaflet.
Estonian: Faslodexi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Faslodex is available as a solution for injection in prefilled syringes (250 mg).
Estonian: Faslodexi turustatakse süstelahusena eeltäidetud süstaldes (250 mg).
English: This is a summary of the European public assessment report (EPAR) for Faslodex.
Estonian: See on ravimi Faslodex Euroopa avaliku hindamisaruande kokkuvõte.
English: What is Faslodex and what is it used for?
Estonian: Mis on Faslodex ja milleks seda kasutatakse?
English: It is not intended to provide practical advice on how to use Faslodex.
Estonian: Hindamisaruandes ei anta Faslodexi kasutamise praktilisi nõuandeid.
English: The dose is given as two injections, each given into the muscle of one buttock over one to two minutes.
Estonian: Annus manustatakse kahe süstina - üks süst kummassegi tuharalihasesse 1-2 minuti jooksul.
English: Faslodex is an anti-oestrogen medicine used to treat advanced or metastatic breast cancer (cancer that has spread to other parts of the body) in the following patients:
Estonian: Faslodex on antiöstrogeen, mida kasutatakse kaugelearenenud või metastaatilise rinnavähi (kui vähk on levinud organismis ka mujale) raviks järgmistel patsientidel:
English: In addition, the medicine is effective in combination with palbociclib in patients with HR-positive, HER-2 negative breast cancer.
Estonian: Peale selle on ravim efektiivne kasutamisel koos palbotsikliibiga HR-positiivse HER2-negatiivse rinnavähiga patsientidel.
English: • postmenopausal women with a type of breast cancer known as ‘oestrogen-receptor positive cancer' who have not previously had hormonal treatment, or whose cancer had come back after treatment with another anti-oestrogen;
Estonian: • menopausijärgses eas naised, kelle rinnavähk on östrogeeniretseptor-positiivne ja kes ei ole varem saanud hormoonravi või kelle vähk on pärast muu antiöstrogeeniga ravimist taastunud;
English: What are the risks associated with Faslodex?
Estonian: Mis riskid Faslodexiga kaasnevad?
English: For practical information about using Faslodex, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Faslodexi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Why is Faslodex approved?
Estonian: Miks Faslodex heaks kiideti?
English: The most common serious side effects were low levels of white and red blood cells, low levels of blood platelets, infections, increased liver enzyme levels and tiredness.
Estonian: Kõige sagedamad rasked kõrvalnähud olid vere valge- ja punaliblede vähesus, vereliistakute vähesus, infektsioonid, maksaensüümide sisalduse suurenemine ja väsimus.
English: As a result, the cancer cells are not stimulated to grow by oestrogen and this slows down the growth of the tumour.
Estonian: Selle tulemusena ei stimuleeri östrogeen vähirakkude vohamist ja vähkkasvaja kasv aeglustub.
English: In women with this type of breast cancer, Faslodex is used in combination with palbociclib (another cancer medicine).
Estonian: Sellist tüüpi rinnavähiga naistel kasutatakse Faslodexi koos palbotsikliibiga (samuti vähiravim).
English: Faslodex contains the active substance fulvestrant.
Estonian: Faslodex sisaldab toimeainena fulvestranti.
English: For more information about treatment with Faslodex, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Faslodexiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The active substance in Faslodex, fulvestrant, is an anti-oestrogen.
Estonian: Faslodexis toimeainena sisalduv fulvestrant on antiöstrogeen.
English: When used in combination with palbociclib, the most common side effects with Faslodex (seen in more than 2 patients in 10) are low levels of white and red blood cells, low blood platelet counts, infections, tiredness, nausea, stomatitis (inflammation of the lining of the mouth) and diarrhoea.
Estonian: Kasutamisel koos palbotsikliibiga on Faslodexi kõige sagedamad kõrvalnähud (esinenud enam kui 2 patsiendil 10st) vere valge- ja punaliblede vähesus, vereliistakute vähesus, infektsioonid, väsimus, iiveldus, stomatiit (suu limaskesta põletik) ja kõhulahtisus.
English: For the full list of all side effects and restrictions with Faslodex, see the package leaflet.
Estonian: Faslodexi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: It blocks the receptors for oestrogen on cells and causes the number of oestrogen receptors to fall.
Estonian: See blokeerib östrogeeniretseptorid vähirakkude pinnal ja vähendab seega östrogeeniretseptorite hulka.
English: Five main studies showed that Faslodex is effective at prolonging the length of time patients live without their disease getting worse.
Estonian: Viies põhiuuringus tõendati, et Faslodex on efektiivne patsientide progresseerumiseta elumuse (ajavahemik, mil patsiendid elasid haiguse süvenemiseta) pikendamisel.
English: When Faslodex is used on its own, the most common side effects (seen in more than 1 patient in 10) are injection-site reactions (such as pain or inflammation), weakness, nausea (feeling sick) and increased liver enzyme levels in the blood (a sign of liver problems).
Estonian: Kasutamisel ainsa ravimina on Faslodexi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) süstekoha reaktsioonid (nt valu või põletik), nõrkus, iiveldus ja maksaensüümide sisalduse suurenemine veres (viitab maksaprobleemidele).
English: • women with a type of breast cancer known as ‘HR-positive, HER-2 negative cancer' who have previously had hormonal treatment.
Estonian: • HR-positiivse HER2-negatiivse rinnavähiga (teatav vähivorm) patsiendid, kes on varem saanud hormoonravi.
English: The fourth study, in 462 women with advanced or metastatic breast cancer who had not been treated with hormonal therapy, showed that women treated with Faslodex (500 mg once a month) lived for an average of 16.6 months without their disease getting worse, compared with 13.8 months for women given anastrozole.
Estonian: Neljandas uuringus, milles osales 462 kaugelearenenud või metastaatilise rinnavähiga naist, kes ei olnud varem saanud hormoonravi, oli keskmine progresseerumiseta elumus Faslodexi (annuses 500 mg kord kuus) kasutanud naistel 16,6 kuud ja anastrosooli kasutanud naistel 13,8 kuud.
English: A third study in 736 women showed that the higher dose of 500 mg of Faslodex was more effective than 250 mg: women receiving the higher dose lived for an average of 6.5 months without their disease getting worse, compared with 5.5 months in those receiving the lower dose.
Estonian: Kolmandast uuringust (milles osales 736 naist) nähtus, et Faslodexi 500 mg annus oli efektiivsem kui 250 mg annus: suuremat annust kasutanud naistel oli keskmine progresseerumiseta elumus 6,5 kuud ja väiksemat annust kasutanud naistel 5,5 kuud.
English: Studies showed that Faslodex, an anti-oestrogen medicine, is effective at prolonging the time patients with oestrogen-receptor positive breast cancer can live without their disease getting worse.
Estonian: Uuringutes tõendati, et antiöstrogeen Faslodex on efektiivne östrogeeniretseptor-positiivse rinnavähiga patsientide progresseerumiseta elumuse pikendamisel.
English: Two of these studies in 851 women showed that Faslodex was as effective as another medicine, anastrozole: women receiving Faslodex lived for an average of 5.4 months without their disease getting worse, compared with 4.1 months for those taking anastrozole.
Estonian: Kahes nendest uuringutest (milles osales 851 naist) oli Faslodex sama efektiivne kui teine ravim anastrosool: Faslodexi kasutanud naistel oli keskmine progresseerumiseta elumus 5,4 kuud ja anastrosooli kasutanud naistel 4,1 kuud.
English: Finally, a study investigating the use of Faslodex in combination with palbociclib in 521 women with (HR)-positive (HER2)-negative advanced or metastatic breast cancer showed that women treated with Faslodex plus palbociclib lived for an average of 9.2 months without their disease getting worse, compared with 3.8 months for women given Faslodex on its own.
Estonian: Viiendas uuringus, milles vaadeldi Faslodexi kasutamist koos palbotsikliibiga HR-positiivse HER2negatiivse kaugelearenenud või metastaatilise rinnavähiga naistel (521 patsienti), oli keskmine progresseerumiseta elumus Faslodexi koos palbotsikliibiga kasutanud naistel 9,2 kuud ja Faslodexi ainsa ravimina kasutanud naistel 3,8 kuud.
English: How does Faslodex work?
Estonian: Kuidas Faslodex toimib?
English: What benefits of Faslodex have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Faslodexi kasulikkus?